Şizofreni Hastalarında Serum Osteopontin Düzeylerinin Sağlıklı Kontrollerle Karşılaştırılması

Amaç: Şizofreni hastalarının yaşam tarzlarından dolayı osteoporoz (OP) ve kırık riski altındadırlar. Bu çalışmada, kemik döngüsünde önemli rolü olan ve osteoporotik sürece katkı sağlayan osteopontin (OPN) belirtecinin, şizofreni hastaları ve kontrol grubundaki düzeylerini karşılaştırılması amaçlanmıştır. Gereç ve Yöntem: Bu çalışmaya, Atatürk Üniversitesi Araştırma Hastanesine Haziran 2019-Eylül 2019 tarihleri arasında Psikyatri polikliniğine başvuran ve/veya servisinde yatan 18-65 yaş arasındaki şizofreni tanısı alan hastalardan çalışmaya katılmayı kabul eden, en az 2 aydır travma ve deformite öyküsü bulunmayan hastalardan, kontrol grubu ise psikiyatrik, travma ve deformite öyküsü olmayan, 18-65 yaş arasında, hasta grubu ile yaş, cinsiyet ve eğitim durumu açısından benzer kişilerden oluşturuldu. G*Power3.1 programı kullanılarak yapılan Power analizi sonucunda tespit edilen örneklem sayısı toplam 110 kişi (kontrol: 55, hasta: 55) olarak belirlendi. Şizofreni tanısı konulan hastaların her birinden alınan serum örneklerinde osteopontin düzeyleri ELISA yöntemi ile ölçüldü. Bulgular: Kontrol ve hasta grubuna ait serum OPN düzeyleri incelendiğinde iki grup arasında istatistiksel olarak anlamlı bir fark tespit edilemedi. Sonuç: Araştırmamız da OPN düzeyleri şizofreni hastalarında ve sağlıklı kontrol grubunda benzer olarak bulundu. Şizofrenide OP sık görülmesinde OPN’den daha farklı mekanizmaların etkisi olabileceğini düşünüyoruz.

Comparison of Serum Osteopontin Levels with Healthy Controls in Schizophrenia Patients

Objective: Patients with schizophrenia are at risk of osteoporosis (OP) and fractures due to their lifestyle. In this study, it was aimed to compare the levels of osteopontin (OPN) marker, which has an important role in bone turnover and contributes to the osteoporotic process, in schizophrenia pati-ents and the control group. Material and Method: From this study, patients who applied to the psychiatry outpatient clinic of Atatürk Unıversty Research Hospital between June 2019 and September 2019 and / or who were diagnosed with schizophrenia between the ages of 18-65 years and who did not have a history of trauma and deformity for at least 2 months. The group consisted of 18-65 years old patients with no history of psychiatric, trauma and deformity, and similar people in terms of age, gender and educational background. The number of samples determined as a result of power analysis using the G * Power 3.1 program as 110 (control: 55, patient: 55). In serum samples taken from each of the patients diagnosed with schizophrenia, OPN levels were measured by the ELISA method. Results: When the serum OPN levels of the control and patient groups were examined, no statistically significant difference was detected between the two groups. Conclusion: In our study, OPN levels were similar in schizophrenia patients and control groups. We think that different mechanisms other than OPN may have an effect on the frequent occurrence of osteoporosis in schizophrenia.

PDF

___

1. Hu Y, Fang Z, Yang Y, Rohlsen-Neal D, Cheng F, Wang JJSr. Analyzing the genes related to nicotine addiction or schizophrenia via a pathway and network based approach. Sci Rep 2018; 8: 2894.
2. Döngel BD, Tamam L, Kir GY. Şizofrenide görülen tibbi durumlar/Comorbid medical conditions in schizophrenia. Psikyatride Güncel Yaklaşımlar 2017; 9: 363.
3. Lally J, Sahl AB, Murphy KC, Gaughran F, Stubbs BP. Serum prolactin and bone mineral density in schizophrenia: a systematic review. Clin Psychopharmacol Neurosci 2019; 17 3: 333.
4. Stubbs B, De Hert M, Sepehry A et al. A meta‐analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand 2014; 130: 470-86.
5. Stubbs B, Gaughran F, Mitchell AJ et al. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Acta Psychiatr Scand 2015; 37: 126-33.
6. Naidoo U, Goff D, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28: 97-108.
7. Dogan BS, Bulut S, Görkem AD et al The effect of antipsychotics on bone mineral density and sex hormones in male patients with schizophrenia. Psychiatr Danub 2016; 28: 255-62.
8. Kıngır ZB, Kumral ZNÖ, Çam ME et al Effects of dapagliflozin in experimental sepsis model in rats. Ulus Travma Acil Cerrahi Derg 2019; 25: 213-21.
9. Okita K, Kanahara N, Nishimura M et al Second-generation antipsychotics and bone turnover in schizophrenia. Schizophr Res 2014; 157: 137-41.
10. Naidoo U, Goff D, Klibanski AJP. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28: 97-108.
11. Szulc PP, Endocrinology RC, Metabolism. Bone turnover: Biology and assessment tools. Best Pract Res Clin Endocrinol Metab 2018; 32: 725-38.
12. Pietrzyk B, Smertka M, Chudek JM. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders. Adv Clin Exp Med 2017; 26: 1283-91.
13. Akçay YŞ, Sarıfakıoğlu B, Şengül İ, Çetin N. Yeni tanı alan postmenopozal osteoporozda kemik döngüsü belirteçleri kırık riski ile ilişkili midir? Kesitsel, klinik çalışma. Türk Osteoporoz Dergisi 2015; 21: 58-62.
14. Standal T, Borset M, Sundan AO. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 2004; 26: 179-84.
15. Icer MA, Gezmen K. The multiple functions and mechanisms of osteopontin. Clin Biochem 2018; 59: 17-24.
16. Mazzali M, Kipari T, Ophascharoensuk V, Wesson J, Johnson R, Hughes JJQ. Osteopontin-a molecule for all seasons. Qjm 2002; 95: 3-13.
17. Sase SP, Ganu JV, Nagane NG. Osteopontin: A novel protein molecule. Indian Medical Gazette 2012: 62-6.
18. Addison WN, Masica DL, Gray JJ, McKee MD. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25: 695-705.
19. Suzuki K, Zhu B, Rittling SR et al. Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res 2002; 17: 1486-97.
20. Luukkonen J, Hilli M, Nakamura M et al. Osteoclasts secrete osteopontin into resorption lacunae during bone resorption. Histochem Cell Biol 2019; 151: 475-87.
21. Singh A, Gill G, Kaur H, Amhmed M, Jakhu HJPio. Role of osteopontin in bone remodeling and orthodontic tooth movement: a review. Prog Orthod 2018; 19: 1-8.
22. Chatakun P, Núñez-Toldrà R, López ED et al. The effect of five proteins on stem cells used for osteoblast differentiation and proliferation: a current review of the literature. Cell Mol Life Sci 2014; 71: 113-42.
23. Huan JL, Xing L, Qin XJ et al. Expression and clinical significance of osteopontin in calcified breast tissue. Asian Pac J Cancer Prev 2012; 13: 5219-23.
24. Filardi T, Carnevale V, Massoud R et al. High serum osteopontin levels are associated with prevalent fractures and worse lipid profile in post-menopausal women with type 2 diabetes. J Endocrinol Invest 2019; 42: 295-301.
25. Özsoy S, Eşel E, Turan T ve ark. Depresyonlu hastalarda kemik mineral yoğunluğunda değişiklik var mı. Türk Psikiyatri Dergisi 2005; 16: 77-82.
26. Cho EH, Cho KH, Lee HA, Kim S. High serum osteopontin levels are associated with low bone mineral density in postmenopausal women. J Korean Med Sci 2013; 28: 1496-9.
27. Ergan SA, Yiğitbaşi T, Yilmaz G, Sarikaya NO, Arslan B. Romatoid Artritli Hastalarda Plazma Osteopontin Düzeyi ve Hastalık Aktivasyonuyla İlişkisi. Türk Fiz Tıp Rehab Derg 2014; 60 (Özel Sayı 1): 30-5.
28. Karakuş G, Kocal Y, Sert DD. Şizofreni: Etyoloji, klinik özellikler ve tedavi. Arşiv Kaynak Tarama Dergisi 2017; 26: 251-67.
29. Gupta AK, Kumar GK, Rani K et al. 2D-Dige as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine-dictated states of Parkinson’s disease and schizophrenia. Neuropsychiatr Dis Treat 2019; 15: 1031.